Study: Rosiglitazone may delay progression of eye disease

A study of 124 diabetes patients showed that rosiglitazone reduced the risk of developing proliferative diabetic retinopathy or deterioration of visual acuity by curbing the formation of new blood vessels. Researchers, however, said larger studies need to be conducted before they can recommend the drug to treat the condition.

View Full Article in:

Washington Post (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY